Genedrive PLC Application for Listing & Total Voting Rights
2024年3月20日 - 12:53AM
RNS Regulatory News
RNS Number : 4755H
Genedrive PLC
19 March 2024
genedrive
plc
("genedrive" or the
"Company")
Application for
Listing
Total Voting
Rights
genedrive plc (AIM: GDR), the point
of care pharmacogenetic testing company, confirms that in order to
support the further drawdown and delivery of its £5M Equity
Prepayment facility that was announced on 31 March 2023,
application has been made for the Admission to trading on AIM of
4,100,000 new Ordinary Shares of 1.5p each ("New Ordinary
Shares"). Admission of the New Ordinary Shares ("Admission")
is expected to occur on 25 March 2024. Following Admission,
the New Ordinary Shares will rank pari passu in all respects with
the Company's existing ordinary shares.
Following Admission the Company's
issued share capital will consist of 138,450,816 Ordinary Shares of
1.5p each and this figure may be used by shareholders as the
denominator for the calculations by which they should determine if
they are required to notify their interest in, or change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further details please
contact:
genedrive plc
|
+44 (0)161
989 0245
|
James Cheek: CEO / Russ Shaw:
CFO
|
|
|
|
Peel
Hunt LLP (Nominated Adviser and Broker)
|
+44 (0)20
7418 8900
|
James Steel / Patrick
Birkholm
|
|
|
|
Walbrook PR Ltd (Media & Investor
Relations)
|
+44 (0)20
7933 8780 or genedrive@walbrookpr.com
|
Anna Dunphy
|
+44
(0)7876 741 001
|
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic
testing company developing and commercialising a low cost, rapid,
versatile, simple to use and robust point of need pharmacogenetic
platform for the diagnosis of genetic variations. This helps
clinicians to quickly access key genetic information that will help
them make the right choices over the right medicine or dosage to
use for an effective treatment. Based in the UK, the Company is at
the forefront of work on Point of Care pharmacogenetics.
Pharmacogenetics looks at how your genetics impacts a medicines
ability to work for you. Therefore, by using pharmacogenetics,
medicines can be made safer and more effective. The Company has
launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which
is a single-use disposable cartridge which circumvents the
requirement for cold chain logistics by providing temperature
stable reagent test kits for use on their proprietary test
platform. This test allows clinicians to make a decision on
antibiotic use within 26 minutes, ensuring vital care is delivered
with no negative impact on the patient pathway.
The Company has a clear commercial
strategy focused on accelerating growth through maximising
in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVRGPUGAWUPCGAB
Genedrive (LSE:GDR)
過去 株価チャート
から 5 2024 まで 6 2024
Genedrive (LSE:GDR)
過去 株価チャート
から 6 2023 まで 6 2024